Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry

BACKGROUND: For treatment of genotype 1a (GT1a) infection with elbasvir/grazoprevir, the German guidelines recommend a differentiated approach depending on baseline viral load (BVL). For low BVL ≤800 000 IU/mL, treatment with 12 weeks elbasvir/grazoprevir should be considered, whereas for high BVL &...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinrichsen, Holger, Stoehr, Albrecht, Cornberg, Markus, Klinker, Hartwig, Heyne, Renate, John, Christine, Simon, Karl-Georg, Guenther, Veronika, Martin, Karen, Witte, Vanessa, Zeuzem, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2020
Materias:
Original Articles: Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846287/
https://www.ncbi.nlm.nih.gov/pubmed/32345848
http://dx.doi.org/10.1097/MEG.0000000000001759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846287/
https://www.ncbi.nlm.nih.gov/pubmed/32345848
http://dx.doi.org/10.1097/MEG.0000000000001759

Ejemplares similares